

ASX RELEASE

2 December 2021

AMPLIA AWARDED \$2.1M R&D CASH FLOW LOAN

- Amplia granted \$2.1m non-dilutive Research and Development (R&D) funding facility
- The facility relates to FY2022 R&D expenditure and is in addition to R&D rebate received for the FY2021 Period
- Amplia to accelerate work on its second Focal Adhesion Kinase (FAK) inhibitor, AMP886

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), a clinical-stage company developing new approaches for the treatment for cancer and fibrosis, is pleased to announce it has been advised that the Company’s application for a non-dilutive funding facility (Facility) as part of the Victorian Government’s R&D Cash Flow Loan Initiative (Initiative) has been approved. The Facility will provide a maximum of \$2.1m to be awarded in two tranches: \$1.3m in December 2021 and \$0.8m in the quarter ending 31 March 2022.

The Company will use the funds from the loan to accelerate work on its second Focal Adhesion Kinase (FAK) inhibitor, AMP886, specifically to evaluate new therapeutic opportunities and prepare to initiate preclinical activities designed to support future clinical trials of AMP886. An expanded scope of further studies evaluating the antifibrotic potential of AMP945 is also planned.

Amplia’s CEO and Managing Director, Dr John Lambert, commented that “The first Phase 2 clinical study of our leading FAK inhibitor AMP945 is funded and about to commence. This loan allows us to kick-start work on a second asset, AMP886, earlier and more aggressively than originally planned. We are very grateful to Invest Victoria for their support.”

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.

- End -

For Further Information

Dr. John Lambert
CEO and Managing Director

john@ampliatx.com

www.ampliatx.com

About the Victorian Government’s R&D Cash Flow Loan Initiative

The Victorian Government’s R&D Cash Flow Loan Initiative is administered by Invest Victoria. It is designed to support innovative Victorian small to medium enterprises (SMEs) who are investing in research and development activity to develop the products, services and technologies vital to the State’s future economy. The Initiative offers low-interest loans of A\$0.25-4.0 million on up to 80% of an SME’s forecasted Research & Development Tax Incentive (RDTI) rebate for the period ending 30 June 2022. Interest on Facility advances is variable at the “TCV 11am” loan interest rate (currently 0.265%). Repayment of the Facility is timed to coincide with receipt of the Amplia’s FY2023 R&D Tax offset, expected by 31 October 2023, but may be repaid earlier. The Facility is secured by the FY2022 and FY2023 RDTI refund.

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and fibrosis and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. In addition, the company is pursuing the potential of its FAK inhibitors in pulmonary fibrosis.